|
Combination Therapy to Overcome Resistance to Platinum-Based Chemotherapy
Application
MAST1 inhibitors to overcome resistance to platinum-based chemotherapy, exacerbated by dexamethasone co-administration.
Key Benefits
Co-administration of MAST1 inhibitor and MAST1-stabilizing protein inhibitor abrogates tumor resistance to cisplatin
MAST1 inhibitor, lestaurtinib, has previously reached phase III clinical trials and...
Published: 8/25/2021
Contributor(s): Sumin Kang, Jing Chen
|
|
Repurposed Treatment for Cocaine Use Disorder
Application
Repurposed drug for transcriptomic-driven treatment of cocaine use disorder.
Key Benefits
FDA-approved drug.
Outperformed current targets undergoing clinical trials for CUD at the mRNA level.
Market Summary
In 2018, there were approximately 2.2 million regular users of cocaine in the United States, and 1 million individuals with...
Published: 1/23/2021
Contributor(s): Rohan Palmer, Spencer Huggett
|
|
Natural Antimicrobial Compound to Treat Multidrug Resistant Infections
Application
Pentagalloylglucose and extracts of Anacardiaceae to treat multidrug resistant bacterial and fungal infections.
Key Benefits
Potential compounds to combat multidrug-resistant pathogens.
Natural compound isolated from Schinus plants.
Antibiotic activity against multidrug-resistant bacteria and fungi.
Low likelihood to contribute to...
Published: 12/9/2020
Contributor(s): Cassandra Quave, Francois Chassagne, Lewis Marquez, Micah Dettweiler, Julia Kubanek, Anne Sweeney-Jones, Bhuwan Chhetri
|
|
CFTR Modulators for Treating Rare Forms of Cystic Fibrosis
Application
Small molecules to treat cystic fibrosis and other pulmonary diseases.
Key Benefits
Rescue rare variants of CFTR gene.
Serve as PDE4 inhibitors with strong anti-inflammatory effects.
Market Summary
Cystic fibrosis (CF) is a progressive, genetic disorder that arises from mutations in the cystic fibrosis transmembrane conductance...
Published: 11/2/2020
Contributor(s): Eric Sorscher, Jeong Hong, Haian Fu, Yuhong Du, Huw Davies, Andras Rab, Candela Manfredi, Xun Yang, Zhi Ren
|
|
Small Molecule for Treatment or Prevention of Uremic Cardiomyopathy
Application
Small molecule urea transporter (UT) inhibitors to treat or prevent conditions associated with chronic kidney disease.
Key Benefits
Provides a cardio-protective benefit in CKD patients.
Suppresses cardiac hypertrophy and fibrosis.
Market Summary
Cardiovascular complications commonly occur in patients with chronic kidney disease...
Published: 11/2/2020
Contributor(s): Jeff Sands, Janet Klein, Xiaonan Wang
|
|
Photocaged Cytokines for Cancer Immunotherapy
Application
Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy.
Key Benefits
Prolonged circulation and biased immune cell-selectivity.
Controlled local activation, reduces off-target toxicity.
Requires less frequent dosing.
Market Summary
While recombinant cytokines hold great potential for cancer...
Published: 11/2/2020
Contributor(s): Erik Dreaden, Lacey Perdue, Priscilla Do
|
|
Targeted Theranostic NanoToxin for Treating Metastatic and Drug-resistant Tumors
Application
Magnetic theranostic nano-toxin for imaging and drug delivery applications in cancer therapy.
Key Benefits
Induces tumor cell death via a different biological mechanism, compared to current chemotherapeutics, to overcome drug resistance mechanisms in tumor cells.
Delivers high levels of therapeutic agents into metastatic tumors, while...
Published: 11/2/2020
Contributor(s): Lily Yang, Xiangxue Guo, Hui Mao, Wei Chen
|
|
Additives that Increase Storage and Shelf Life of Platelets
Application
Monoclonal antibody additive that inhibits ectodomain shedding of a platelet glycoprotein to improve platelet storage.
Key Benefits
Current storage techniques allows for limited storage times (5-7 days).
New additive may enable platelet storage at 4°C, increase platelet storage time, and improve quality of stored platelets.
Inhibits...
Published: 11/2/2020
Contributor(s): Renhao Li
|
|
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application
Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition.
Key Benefits
Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors.
Checkpoint inhibitor therapy is FDA-approved and already in use.
Market Summary
Checkpoint blockade...
Published: 10/22/2020
Contributor(s): Eric Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
|
|
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application
Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients.
Key Benefits
Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020
Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
|
Emory UniversityOffice of Technology Transfer